nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

27.02.2016 | Original Article

RGD-K5 PET/CT in patients with advanced head and neck cancer treated with concurrent chemoradiotherapy: Results from a pilot study

verfasst von: Shih-Hsin Chen, Hung-Ming Wang, Chien-Yu Lin, Joseph Tung-Chieh Chang, Chia-Hsun Hsieh, Chun-Ta Liao, Chung-Jan Kang, Lan-Yan Yang, Tzu-Chen Yen

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

Background/Aim

We prospectively investigated the potential usefulness of PET using a new tracer targeting integrin αvβ3 (termed RGD-K5) in patients with head and neck cancer (HNC) undergoing definitive concurrent chemoradiotherapy (CCRT).

Patients and Methods

Newly diagnosed patients with locally advanced HNC scheduled for definitive CCRT were eligible. RDG-K5 PET and FDG PET scans were performed at three different time points (baseline, 2 weeks, and 3 months post-treatment).

Results

Nine patients completed all of the three scans, whereas two patients withdrew after two scans only. Uptake of both RGD-K5 and FDG generally decreased following CCRT. However, the observed decrease did not differ significantly between complete responders and non-responders. At 3 months post-treatment, the uptake of both RGD-K5 and FDG at the main tumors was significantly lower in those who achieved complete responses than in those with residual tumors.

Conclusion

RGD-K5 PET has the potential to identify patients with incomplete responses to CCRT.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.CrossRefPubMed

Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9–22. doi:10.1038/nrc2748.CrossRefPubMedPubMedCentral

Fabricius EM, Wildner GP, Kruse-Boitschenko U, Hoffmeister B, Goodman SL, Raguse JD. Immunohistochemical analysis of integrins alphavbeta3, alphavbeta5 and alpha5beta1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas. Exp Ther Med. 2011;2(1):9–19. doi:10.3892/etm.2010.171.PubMed

Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res. 2006;12(13):3942–9. doi:10.1158/1078-0432.CCR-06-0266.CrossRefPubMed

Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I, et al. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13(22 Pt 1):6610–6. doi:10.1158/1078-0432.CCR-07-0528.CrossRefPubMed

Hsu HW, Wall NR, Hsueh CT, Kim S, Ferris RL, Chen CS, et al. Combination antiangiogenic therapy and radiation in head and neck cancers. Oral Oncol. 2014;50(1):19–26. doi:10.1016/j.oraloncology.2013.10.003.CrossRefPubMed

Sahu N, Grandis JR. New advances in molecular approaches to head and neck squamous cell carcinoma. Anti-Cancer Drugs. 2011;22(7):656–64. doi:10.1097/CAD.0b013e32834249ba.CrossRefPubMedPubMedCentral

Doss M, Kolb HC, Zhang JJ, Belanger MJ, Stubbs JB, Stabin MG, et al. Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans. J Nucl Med. 2012;53(5):787–95. doi:10.2967/jnumed.111.088955.CrossRefPubMed

Wang HM, Hsu CL, Hsieh CH, Fan KH, Lin CY, Chang JT, et al. Concurrent chemoradiotherapy using cisplatin, tegafur, and leucovorin for advanced squamous cell carcinoma of the hypopharynx and oropharynx. Biomed J. 2014;37(3):133–40. doi:10.4103/2319-4170.117893.PubMed

10.

Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149–60. doi:10.3758/BRM.41.4.1149.CrossRefPubMed

11.

Terry SY, Abiraj K, Lok J, Gerrits D, Franssen GM, Oyen WJ, et al. Can 111In-RGD2 monitor response to therapy in head and neck tumor xenografts? J Nucl Med. 2014;55(11):1849–55. doi:10.2967/jnumed.114.144394.CrossRefPubMed

12.

Rylova SN, Barnucz E, Fani M, Braun F, Werner M, Lassmann S, et al. Does imaging alphavbeta3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy? J Nucl Med. 2014;55(11):1878–84. doi:10.2967/jnumed.114.137570.CrossRefPubMed

13.

Chuang JY, Chang AC, Chiang IP, Tsai MH, Tang CH. Apoptosis signal-regulating kinase 1 is involved in WISP-1-promoted cell motility in human oral squamous cell carcinoma cells. PLoS One. 2013;8(10):e78022. doi:10.1371/journal.pone.0078022.CrossRefPubMedPubMedCentral

14.

Chuang JY, Chen PC, Tsao CW, Chang AC, Lein MY, Lin CC, et al. WISP-1 a novel angiogenic regulator of the CCN family promotes oral squamous cell carcinoma angiogenesis through VEGF-A expression. Oncotarget. 2015;6(6):4239–52.CrossRefPubMedPubMedCentral

15.

Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, et al. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res. 2005;11(17):6270–9. doi:10.1158/1078-0432.CCR-04-1223.CrossRefPubMed

16.

Liao CT, Fan KH, Lin CY, Wang HM, Huang SF, Chen IH, et al. Impact of a second FDG PET scan before adjuvant therapy for the early detection of residual/relapsing tumours in high-risk patients with oral cavity cancer and pathological extracapsular spread. Eur J Nucl Med Mol Imaging. 2012;39(6):944–55. doi:10.1007/s00259-012-2103-2.CrossRefPubMed

17.

Kang CJ, Lin CY, Yang LY, Ho TY, Lee LY, Fan KH, et al. Positive clinical impact of an additional PET/CT scan before adjuvant radiotherapy or concurrent chemoradiotherapy in patients with advanced oral cavity squamous cell carcinoma. J Nucl Med. 2015;56(1):22–30. doi:10.2967/jnumed.114.145300.CrossRefPubMed

18.

Prestwich RJ, Subesinghe M, Gilbert A, Chowdhury FU, Sen M, Scarsbrook AF. Delayed response assessment with FDG-PET-CT following (chemo) radiotherapy for locally advanced head and neck squamous cell carcinoma. Clin Radiol. 2012;67(10):966–75. doi:10.1016/j.crad.2012.02.016.CrossRefPubMed

19.

Ul-Hassan F, Simo R, Guerrero-Urbano T, Oakley R, Jeannon JP, Cook GJ. Can (18)F-FDG PET/CT reliably assess response to primary treatment of head and neck cancer? Clin Nucl Med. 2013;38(4):263–5. doi:10.1097/RLU.0b013e31828165a8.CrossRefPubMed

20.

Karar J, Maity A. Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biol Ther. 2009;8(21):1994–2001.CrossRefPubMedPubMedCentral

21.

Toustrup K, Sorensen BS, Nordsmark M, Busk M, Wiuf C, Alsner J, et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res. 2011;71(17):5923–31. doi:10.1158/0008-5472.CAN-11-1182.CrossRefPubMed

22.

Vassilakopoulou M, Psyrri A, Argiris A. Targeting angiogenesis in head and neck cancer. Oral Oncol. 2015;51(5):409–15. doi:10.1016/j.oraloncology.2015.01.006.CrossRefPubMed

23.

Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res. 2005;11(4):1434–40. doi:10.1158/1078-0432.CCR-04-1870.CrossRefPubMed

24.

Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 2008;9(3):288–96. doi:10.1016/S1470-2045(08)70073-1.CrossRefPubMed

25.

Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell. 2004;5(5):429–41.CrossRefPubMed

26.

Sofia Vala I, Martins LR, Imaizumi N, Nunes RJ, Rino J, Kuonen F, et al. Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS One. 2010;5(6):e11222. doi:10.1371/journal.pone.0011222.CrossRefPubMedPubMedCentral

27.

Bozec A, Sudaka A, Fischel JL, Brunstein MC, Etienne-Grimaldi MC, Milano G. Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. Br J Cancer. 2008;99(1):93–9. doi:10.1038/sj.bjc.6604429.CrossRefPubMedPubMedCentral

28.

Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009;10(3):247–57. doi:10.1016/S1470-2045(09)70002-6.CrossRefPubMedPubMedCentral

29.

Argiris A, Karamouzis MV, Gooding WE, Branstetter BF, Zhong S, Raez LE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2011;29(9):1140–5. doi:10.1200/JCO.2010.33.3591.CrossRefPubMedPubMedCentral

30.

Hainsworth JD, Spigel DR, Greco FA, Shipley DL, Peyton J, Rubin M, et al. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium. Cancer J. 2011;17(5):267–72. doi:10.1097/PPO.0b013e3182329791.CrossRefPubMed

31.

Yoo DS, Kirkpatrick JP, Craciunescu O, Broadwater G, Peterson BL, Carroll MD, et al. Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. Clin Cancer Res. 2012;18(5):1404–14. doi:10.1158/1078-0432.CCR-11-1982.CrossRefPubMed

32.

Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, et al. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2013;24(1):220–5. doi:10.1093/annonc/mds245.CrossRefPubMed

33.

Fury MG, Lee NY, Sherman E, Lisa D, Kelly K, Lipson B, et al. A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. Cancer. 2012;118(20):5008–14. doi:10.1002/cncr.27498.CrossRefPubMed

34.

Yao M, Galanopoulos N, Lavertu P, Fu P, Gibson M, Argiris A, et al. Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck. Head Neck. 2015;37(11):1665–71. doi:10.1002/hed.23813.CrossRefPubMed

35.

Fury MG, Xiao H, Sherman EJ, Baxi S, Smith-Marrone S, Schupak K, et al. Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma. Head Neck. 2015. doi:10.1002/hed.24041.PubMed

36.

Vermorken JB, Peyrade F, Krauss J, Mesia R, Remenar E, Gauler TC, et al. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part). Ann Oncol. 2014;25(3):682–8. doi:10.1093/annonc/mdu003.CrossRefPubMedPubMedCentral

Titel: RGD-K5 PET/CT in patients with advanced head and neck cancer treated with concurrent chemoradiotherapy: Results from a pilot study
verfasst von: Shih-Hsin Chen
Hung-Ming Wang
Chien-Yu Lin
Joseph Tung-Chieh Chang
Chia-Hsun Hsieh
Chun-Ta Liao
Chung-Jan Kang
Lan-Yan Yang
Tzu-Chen Yen
Publikationsdatum: 27.02.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3345-1

Springer Medizin

Abstract

Background/Aim

Patients and Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2016

18F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease

Severe early basal ganglia hypometabolism in neurodegeneration with brain iron accumulation

18F-FDG PET/CT in patients with idiopathic retroperitoneal and mediastinal fibrosis

William T. O’Brien Sr. (Ed.), Top 3 Differentials in Neuroradiology: A Case Review. Thieme Medical Publishers, Inc., 2015. ISBN 978-1- 60406-723-1

Direct comparison of 68Ga-DOTA-TOC and 18F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle

18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial